02-Mar-2021 - CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences

Joint CeMM-IST Austria start-up develops new class of drugs targeting solute carrier proteins

Solgate closes its first financing round with IST cube and private investors

Solgate GmbH, an Austrian early-stage biotech company, announces the completion of its first financing round from a group of venture and private investors.

Solgate was incorporated in 2020 by a high-profile founding team and with intellectual property from the leading research institutions CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, and IST Austria (Institute of Science and Technology Austria), with support from the Austrian business agency (AWS). The company applies methods from chemistry, cell biology, and advanced analytics to develop drugs that target membrane transporters known as solute carrier proteins (SLCs) - a novel, largely unexploited, and highly promising class of drug targets. The company is located at IST PARK, the technology park adjacent to the campus of IST Austria.

Alexander Schwartz, Partner at IST cube, comments: “We are very happy to work with Solgate, where a top-team of renowned researchers who have pioneered the field of SLCs, are applying a new approach towards drug discovery. On top of the synergies among the founding team, we see additional synergies emerging from the cooperation of scientists from different institutions, in this case IST Austria and CeMM. We are happy to participate in this investment round and are looking forward to the next steps together with the founders and fellow investors.”

Giulio Superti-Furga, CeMM Director, and Co-Founder of Solgate, remarks: “Solgate is the first start-up born out of a cooperation between CeMM and IST Austria and the sixth startup company, which has been created based on CeMM’s intellectual property and know-how. We are grateful for the trust of the investors and are certain that Solgate will be a great success.”

“Membrane transporters, such as SLCs are exciting therapeutic targets that show promise in the development of breakthrough treatments for challenging diseases.  We see an opportunity for Solgate to benefit from advances in technology and SLC biology, to create and develop new drug candidates targeting SLCs. We are thrilled to have the support and domain expertise of our investors and look forward to accomplishing our vision even more rapidly together”, adds Ariel Bensimon, co-founder and CEO of Solgate.

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences

Recommend news PDF version / Print Add news to watchlist

Share on

Facts, background information, dossiers
More about CeMM
  • News

    Hematoxylin as a killer of CALR mutant cancer cells

    Patients with myeloproliferative neoplasm (MPN), a group of malignant diseases of the bone marrow, often have a carcinogenic mutated form of the calreticulin gene (CALR). Scientists of the research group of Robert Kralovics, Adjunct Principal Investigator at the CeMM Research Center for Mol ... more

    Study of hundreds of proteins in parallel

    CeMM researchers have developed a highly scalable method which allows for the study of hundreds of proteins in parallel in order to monitor the changes of their levels and localization in the cell. This novel strategy is a notable contribution, not only to drug development for future treatm ... more

    Allergic immune responses help fight bacterial infections

    Researchers from CeMM Research Center of Molecular Medicine of the Austrian Academy of Sciences, the Medical University of Vienna and Stanford University School of Medicine, have found that a module of the immune system, which is best known for causing allergic reactions, plays a key role i ... more

  • Research Institutes

    CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences

    CeMM is an international, independent and interdisciplinary research Center in Molecular Medicine of the Austrian Academy of Sciences. “From the clinic to the clinic”: Driven by medical needs, CeMM integrates basic research and clinical expertise to pursue innovative diagnostic and therape ... more